Page last updated: 2024-12-05

molsidomine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Molsidomine is a nitric oxide (NO) donor drug used to treat angina, a condition characterized by chest pain due to reduced blood flow to the heart. It works by releasing NO in the body, which relaxes blood vessels and improves blood flow. Molsidomine is synthesized by reacting 3-hydroxy-2-oxo-1,2,3,4-tetrahydroquinoline with 1-chloro-2,2-dicyanoethylene in a multi-step process. It is often studied as a potential treatment for pulmonary hypertension and other cardiovascular diseases, as it has been shown to improve blood vessel function and reduce inflammation. '

Molsidomine: A morpholinyl sydnone imine ethyl ester, having a nitrogen in place of the keto oxygen. It acts as NITRIC OXIDE DONORS and is a vasodilator that has been used in ANGINA PECTORIS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

molsidomine : A member of the class of oxadiazoles that is 1,2,3-oxadiazole substituted by morpholin-4-yl and (ethoxycarbonyl)azanidyl groups at positions 3 and 5, respectively. It is used as a vasodilator drug for the treatment of myocardial ischemic syndrome and congestive heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4238
CHEBI ID31861
MeSH IDM0014003
PubMed CID5353788
CHEMBL ID1256353
CHEMBL ID1329455
CHEMBL ID4059924
CHEBI ID92623
SCHEMBL ID34019
MeSH IDM0014003

Synonyms (137)

Synonym
molsidomine
molsidomin
LP00725
HMS3369H14
HMS3373B04
M2524
CHEBI:31861
AKOS030254869
molsidomine 1.0 mg/ml in methanol
(z)-5-(ethoxycarbonylimino)-3-morpholino-5h-1,2,3-oxadiazol-3-ium-2-ide
XLFWDASMENKTKL-NTMALXAHSA-N
Q408132
sin-10;morsydomine
C74337
AC-7473
smr001233224
MLS002153869
MLS001146942
AKOS015843340
corvaton
molsidolat
EU-0100725
25717-80-0
PRESTWICK_863
NCGC00015661-02
NCGC00015661-01
cas-25717-80-0
lopac-m-2901
PRESTWICK3_000547
AB00513859
D01320
molsidomine (jan/usan/inn)
NCGC00024136-05
NCGC00024136-04
n-ethoxycarbonyl-3-morpholinosydnonimine
sin-10
molsidominum [inn-latin]
sydnone imine, n-(ethoxycarbonyl)-3-(4-morpholinyl)-
einecs 247-207-4
brn 3999414
morsydomine
sydnopharm
motazomin
n-carboxy-3-morpholinosydnone imine ethyl ester
molsidomina [inn-spanish]
MLS000028573 ,
smr000058990
SPECTRUM1500673
BPBIO1_000653
BSPBIO_000593
NCGC00024136-06
NCGC00024136-03
NCGC00024136-07
NCGC00015661-05
HMS2092G20
HMS2089L03
NCGC00015661-10
HMS501O05
(1e)-1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
HMS1569N15
HMS1921A16
1-ethoxy-n-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate
HMS3262A12
HMS2096N15
CHEMBL1256353
cas-276
CHEMBL1329455
(1e)-1-ethoxy-n-(3-morpholinooxadiazol-3-ium-5-yl)methanimidate;molsidomine
A817988
nsc-757398
dtxcid8025171
tox21_110192
dtxsid0045171 ,
HMS2232F20
HMS2235B12
S4664
AKOS015962928
CCG-40069
NCGC00015661-03
NCGC00015661-09
NCGC00015661-08
NCGC00015661-07
NCGC00015661-04
NCGC00015661-06
molsidomina
molsidomine [usan:inn:ban:jan]
nsc 757398
covarsal
molsidominum
d46583g77x ,
cas 276
unii-d46583g77x
n-(ethoxycarbonyl)-3-(4-morpholino)sydnone imine
AKOS015900360
molsidomine [inn]
molsidomine [mi]
molsidomine [who-dd]
molsidomine [ep monograph]
molsidomine [usan]
molsidomine [mart.]
molsidomine [jan]
CCG-220547
SCHEMBL34019
tox21_110192_1
NCGC00015661-12
KS-5160
AB00513859-02
NCGC00261410-01
CS-4625
tox21_500725
(1e)-1-ethoxy-n-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]methanimidate
cid_5353788
(1e)-1-ethoxy-n-(3-morpholinooxadiazol-3-ium-5-yl)formimidate
bdbm39912
(1e)-1-ethoxy-n-(3-morpholin-4-yl-1,2,3-oxadiazol-3-ium-5-yl)methanimidate
W-107222
HY-B1069
HMS3649M16
OPERA_ID_238
AB00052152_14
mfcd00869301
n-[3-(4-morpholinyl)-5-oxadiazol-3-iumyl]carbamic acid ethyl ester
DB09282
AKOS026749793
CHEBI:92623
SR-05000001464-3
sr-05000001464
SR-05000001464-1
SBI-0050703.P004
HMS3713N15
bdbm50248123
(ethoxycarbonyl)(3-morpholino-1,2,3-oxadiazol-3-ium-5-yl)amide
SDCCGSBI-0050703.P005
NCGC00015661-16
CHEMBL4059924
EN300-33061232
5-[(ethoxycarbonyl)azanidyl]-3-(morpholin-4-yl)-1,2,3lambda5-oxadiazol-3-ylium

Research Excerpts

Overview

Molsidomine is an effective long-acting anti-anginal agent with nitrate-like effects. It is a prodrug of nitric oxide (NO) and is used in the treatment of coronary heart disease.

ExcerptReferenceRelevance
"Molsidomine is a well-known vasodilatating, antianginal drug. "( New approach to molsidomine active metabolites coming from the results of 2 models of experimental cardiology.
Krzemiński, TF; Mitręga, KA; Porc, M; Żorniak, M, 2017
)
2.24
"Molsidomine (Mol) is a drug used for the treatment of coronary artery disease."( Molsidomine ameliorates experimental allergic encephalomyelitis in Lewis rats.
Choi, BM; Chung, HT; Jang, SI; Jung, S; Kwak, HJ; Oh, GS; Pae, HO, 2003
)
2.48
"Molsidomine (MO) is an established drug in treatment of coronary heart disease. "( [Effects of molsidomine on changes in oxidant/antioxidant status of rat erythrocytes].
Maletić, SD; Ognjanović, BI; Saicić, ZS; Spasić, MB; Stajn, AS; Zikić, RV, 2003
)
2.14
"Molsidomine is an effective long-acting anti-anginal agent with nitrate-like effects and should be a useful addition to the drugs already in use."( Molsidomine, an effective long-acting anti-anginal drug.
Balakumaran, K; Chadha, DR; Hugenholtz, PG; Tijssen, JG, 1983
)
2.43
"Molsidomine is a derivative of the sydnonimines and is a long-acting vasodilator that may be effective in the treatment of chronic stable angina pectoris. "( Long-term effects of molsidomine on exercise tolerance in patients with exertional angina pectoris.
Kawaguchi, Y; Kawakita, S; Kinoshita, M; Motomura, M; Sawamura, M; Takayama, Y, 1983
)
2.03
"(2) Molsidomine is a potent agent for reducing I size."( Comparison of various methods for assessing infarct-size in the dog.
Göbel, H; Kettenbach, B; Martorana, PA; Nitz, RE,
)
0.61
"Molsidomine is a prodrug of nitric oxide (NO) and is used in the treatment of coronary heart disease. "( Effect of molsidomine and free radical scavengers on the pulmonary thromboembolism in mice.
Dikshit, M; Seth, P; Srimal, RC, 1993
)
2.13
"Molsidomine is a prodrug for the formation of nitric oxide (NO). "( Clinical pharmacokinetics of molsidomine.
Parnham, MJ; Rosenkranz, B; Winkelmann, BR, 1996
)
2.03
"Molsidomine is an established drug for the treatment of coronary heart disease. "( Molsidomine.
Reden, J, 1990
)
3.16
"Molsidomine (M) is a recent nitrates-like drug acting for a longer time than the classical nitrates."( Acute effect of molsidomine on pulmonary circulation of patients with chronic obstructive pulmonary disease.
Frans, A; Lampert, E; Mwepu, AK, 1989
)
1.34
"Molsidomine (M) is a new antianginal drug which induces a peripheral venous pooling and decreases pulmonary artery and pulmonary venous pressures. "( Effect of molsidomine on the lung diffusing capacity of normal men.
Frans, A; Lampert, E; Lebecque, P; Mwepu, AK; Piret, L, 1988
)
2.12
"Molsidomine seems to be a very promising drug for the treatment of effort and spontaneous angina."( Evaluation of the chronic antianginal effect of molsidomine.
Dalla-Volta, S; Razzolini, R; Scorzelli, L, 1985
)
1.25

Effects

Oral molsidomine has a protective effect on gastric mucosa against damage induced by ulcerogenic agents.

ExcerptReferenceRelevance
"Oral molsidomine has a protective effect on gastric mucosa against damage induced by ulcerogenic agents. "( Protective effect of the nitric oxide donor molsidomine on indomethacin and aspirin-induced gastric injury in rats.
Khuri, M; Mourad, FH; Nassar, CF; Shouaib, F, 2000
)
1.08
"Thus molsidomine has an early positive effect on FMD in addition to a delayed vasodilator effect."( Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease.
Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Pelle, G; Sediame, S, 2000
)
2.2
"Oral molsidomine has a protective effect on gastric mucosa against damage induced by ulcerogenic agents. "( Protective effect of the nitric oxide donor molsidomine on indomethacin and aspirin-induced gastric injury in rats.
Khuri, M; Mourad, FH; Nassar, CF; Shouaib, F, 2000
)
1.08
"Thus molsidomine has an early positive effect on FMD in addition to a delayed vasodilator effect."( Molsidomine improves flow-dependent vasodilation in brachial arteries of patients with coronary artery disease.
Adnot, S; Belhassen, L; Benacerraf, S; Carville, C; Dubois-Randé, JL; Pelle, G; Sediame, S, 2000
)
2.2

Actions

Molsidomine plays a role in attenuating reperfusion injury of the small intestine by depression of tissue MDA levels and MIS. It regulates post-ischemic intestinal perfusion while restoring the intestinal microcirculatory blood flow.

ExcerptReferenceRelevance
"Molsidomine tended to increase MAP duration by 20.7 ± 13.4 ms."( Nitric oxide delays atrial tachycardia-induced electrical remodelling in a sheep model.
Heidbüchel, H; Holemans, P; Janssens, S; Lenaerts, I; Pokreisz, P; Sipido, KR; Willems, R, 2011
)
1.09
"Molsidomine plays a role in attenuating reperfusion injury of the small intestine by depression of tissue MDA levels and MIS and regulates post-ischemic intestinal perfusion while restoring the intestinal microcirculatory blood flow and histologic injury."( The nitric oxide donor molsidomine prevents ischemia/reperfusion injury of the adult rat small intestine.
Aldemir, M; Dokucu, AI; Kilinç, N; Oztürk, H; Sahin, AH; Yağmur, Y, 2003
)
1.35
"The molsidomine-induced increase in the exercise tolerance was maintained throughout the long-term medication (537 +/- 268 W x min)."( Acute and chronic effects of molsidomine on pulmonary artery pressure and work capacity in patients with coronary heart disease.
Eggeling, T; Hilger, HH; Jansen, W; Meyer, L; Tauchert, M, 1987
)
1.05

Treatment

Molsidomine treatment significantly improved vital sign, renal functions, and oxidative stress in DN rats in a dose-dependent manner. Treatment almost completely prevented the I-R-induced renal dysfunction, and survival reached 100%.

ExcerptReferenceRelevance
"Molsidomine treatment significantly improved vital sign, renal functions, and oxidative stress in DN rats in a dose-dependent manner."( Therapeutic insight into molsidomine, a nitric oxide donor in streptozotocin-induced diabetic nephropathy in rats.
Minaz, N; Razdan, R,
)
1.16
"Molsidomine treatment almost completely prevented the I-R-induced renal dysfunction, and survival reached 100%."( Intrarenal administration of molsidomine, a molecule releasing nitric oxide, reduces renal ischemia-reperfusion injury in rats.
Arevalo, M; Eleno, N; Garcia-Criado, FJ; Lopez-Novoa, JM; Rodriguez-Peña, A, 2004
)
1.34
"Molsidomine treatment also attenuated the serum levels of TNF-alpha."( Reversal of iron-induced nephrotoxicity in rats by molsidomine, a nitric oxide donor.
Chopra, K; Gupta, A; Sharma, S, 2008
)
1.32
"Molsidomine treated rats (G-III) were alive and healthy at day 7."( The effects of the nitric oxide donor molsidomine prevent in warm ischemia-reperfusion injury of the rat renal--a functional and histophatological study.
Aldemir, M; Büyükbayram, H; Dokucu, AI; Otçu, S; Oztürk, H, 2001
)
1.3
"Molsidomine protected the treated animals from early (10 min) post-ischaemic ventricular fibrillation (0 of 20 vs 6 of 20, P = 0.0202), reduced the incidence of overall post-occlusion ventricular fibrillation (3 of 20 vs 10 of 20, P = 0.0407) and improved the total survival rate (P = 0.0067)."( Molsidomine prevents post-ischaemic ventricular fibrillation in dogs.
Cano, JP; Guillen, JC; Jouve, R; Langlet, F; Puddu, PE; Rolland, PH; Serradimigni, A, 1986
)
2.44
"Molsidomine treatment 15 min prior to repeated intracoronary LTD4 application attenuated vasoconstrictor response to LTD4 and the subsequent elevation in total coronary vascular resistance."( Molsidomine on cardiovascular leukotriene D4 actions.
Abram, TS; Fiedler, VB, 1985
)
2.43
"Treatment with molsidomine significantly improved motor coordination, paw withdrawal threshold, mechanical threshold, and nerve conduction velocity."( Molsidomine ameliorates diabetic peripheral neuropathy complications in Wistar rats.
Minaz, N; Nayak B, P; Pasha, K, 2021
)
2.4
"Pretreatment with molsidomine significantly reduced disease activity index, colon mass index, colonic macroscopic and histological damage."( Molsidomine alleviates acetic acid-induced colitis in rats by reducing oxidative stress, inflammation and apoptosis.
El-Kashef, DH; Mohamed, NI; Suddek, GM, 2021
)
2.39
"Treatment with Molsidomine reduced mortality to 0%, decreased BT, MPO, pro-inflammatory cytokines and OFR (p<.001) significantly and increased IL-10 and IL-6 production."( Comparative study of bacterial translocation control with nitric oxide donors and COX2 inhibitor.
García-Cenador, MB; García-Criado, FJ; García-García, MI; García-Moro, M; García-Sánchez, E; García-Sánchez, JE; Lorenzo-Gómez, MF; Lozano-Sánchez, F; Sánchez-Conde, MP, 2016
)
0.77
"Treatment with molsidomine (1 mg/kg/day) during cholesterol withdrawal did not affect plaque size but increased the thickness of the subendothelial macrophage-free layer consisting of SMC, and normalized both superoxide production and ecSOD mRNA expression."( Nitric oxide donor molsidomine favors features of atherosclerotic plaque stability during cholesterol lowering in rabbits.
Bult, H; De Cleen, DM; De Meyer, GR; Herman, AG; Knaapen, MW; Kockx, MM; Martinet, W, 2003
)
0.99
"Treatment with molsidomine 3 x 8 mg/day for 6 months does not improve blood rheology or reduce cardiovascular events. "( [Effect of molsidomine on rheological parameters and the incidence of cardiovascular events].
Grebe, OC; Hoffmeister, A; Höher, M; Hombach, V; Kestler, HA; Kochs, M; Koenig, W; Nusser, T; Wöhrle, J, 2003
)
1.06
"4. Treatment with molsidomine (15 mg x kg(-1) day(-1) in drinking water) had the same effects as tempol, except that liver weight was reduced, and potassium and U46619-evoked vasoconstrictions in pulmonary arteries were increased."( The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats.
de Dam, MY; Elmedal, B; Mulvany, MJ; Simonsen, U, 2004
)
0.65
"Mice treated with molsidomine had enhanced liver proteasome activity 6 hours after treatment, but after 24 hours enzyme activity declined below control levels."( Peroxynitrite alters the catalytic activity of rodent liver proteasome in vitro and in vivo.
Donohue, TM; Haorah, J; Krutik, VM; Osna, NA, 2004
)
0.65
"Pretreatment with molsidomine and BQ 610 attenuated the ET-induced reduction of cardiac output (ET-1: -62%; molsidomine+ET-1: -47%; BQ 610+ET-1: -27% different from controls)."( Inotropic effects of endothelin-1: interaction with molsidomine and with BQ 610.
Beyer, ME; Hoffmeister, HM; Hövelborn, T; Kazmaier, S; Nerz, S; Slesak, G, 1999
)
0.88
"Oral treatment with molsidomine (MSDM), a NO donor, began 24 h before IRBP immunization to the end of the experiments, which resulted in a significant inhibition of the disease by clinical and histopathological criteria."( Exogenous nitric oxide inhibits experimental autoimmune uveoretinitis development in Lewis rats by modulation of the Th1-dependent immune response.
Chung, HT; Kim, YM; Kwak, HJ; Pae, HO; Yang, YS, 2001
)
0.63

Toxicity

ExcerptReferenceRelevance
" SIN-1 (< 1 mM) was only slightly toxic to HepG2 cells."( Increased cytotoxicity of 3-morpholinosydnonimine to HepG2 cells in the presence of superoxide dismutase. Role of hydrogen peroxide and iron.
Cederbaum, AI; Gergel, D; Misík, V; Ondrias, K, 1995
)
0.29
"We sought to investigate whether linsidomine chlorhydrate (SIN1, the active metabolite of molsidomine and a nitric oxide donor) has a toxic effect when used chronically for the treatment of impotence."( Intracavernous injection of linsidomine chlorhydrate in monkeys: lack of toxic effect with long-term use.
Brock, GB; Lue, TF; Martinez-Piñeiro, L; von Heyden, B, 1996
)
0.52
"SIN1 appears to be a safe option for the pharmacotherapy of erectile dysfunction."( Intracavernous injection of linsidomine chlorhydrate in monkeys: lack of toxic effect with long-term use.
Brock, GB; Lue, TF; Martinez-Piñeiro, L; von Heyden, B, 1996
)
0.29
" We conclude that exposures to toxic levels of NO cause prolonged disruption of [Ca2+]i homeostatic mechanisms, and that the resulting persistent [Ca2+]i elevations contribute to the delayed neurotoxicity of NO."( Disrupted [Ca2+]i homeostasis contributes to the toxicity of nitric oxide in cultured hippocampal neurons.
Brorson, JR; Zhang, H, 1997
)
0.3
" These results demonstrate that the immediate toxic agent formed from SIN-1 decisively depends on the presence of Hepes."( The critical role of Hepes in SIN-1 cytotoxicity, peroxynitrite versus hydrogen peroxide.
de Groot, H; Kirsch, M; Lomonosova, EE; Rauen, U, 1998
)
0.3
"Microglia have been shown to be immunostimulated by inflammatory cytokines and produce a number of toxic mediators."( Potentiation of N-methyl-D-aspartate-mediated neurotoxicity by immunostimulated murine microglia.
Kim, WK; Ko, KH, 1998
)
0.3
"1 mM SIN-1 were not toxic to MAC-T cells."( Cytotoxic effects of peroxynitrite, polymorphonuclear neutrophils, free-radical scavengers, inhibitors of myeloperoxidase, and inhibitors of nitric oxide synthase on bovine mammary secretory epithelial cells.
Douglass, LW; Ledbetter, TK; Paape, MJ, 2001
)
0.31
"Peroxynitrite, MPO, and histidine are toxic to mammary secretory epithelial cells."( Cytotoxic effects of peroxynitrite, polymorphonuclear neutrophils, free-radical scavengers, inhibitors of myeloperoxidase, and inhibitors of nitric oxide synthase on bovine mammary secretory epithelial cells.
Douglass, LW; Ledbetter, TK; Paape, MJ, 2001
)
0.31
" Furthermore, when cells reached confluence they were highly resistant to the toxic effects of peroxynitrite, hydrogen peroxide, and superoxide."( Role of intracellular calcium mobilization and cell-density-dependent signaling in oxidative-stress-induced cytotoxicity in HaCaT keratinocytes.
Bai, P; Bakondi, E; Csernoch, L; Gergely, P; Gönczi, M; Hunyadi, J; Kovács, L; Pacher, P; Szabó, C; Szabó, E; Virág, L, 2003
)
0.32
" Drug effects on exercise capacity (study 1 only), frequency of anginal attacks and consumption of short-acting itroderivatives, and incidence of adverse events (AEs) were evaluated."( Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies.
Cerreer-Bruhwyler, F; Dubois, C; Famaey, JP; Géczy, J; Messin, R,
)
0.37
"We propose that MOL acts in the liver as a potent scavenger of free radicals, anti-inflammatory and anti-apoptotic effects to prevent the toxic effects of cisplatin, both at the biochemical and histopathological levels."( Molsidomine prevents cisplatin-induced hepatotoxicity.
Bentli, R; Parlakpinar, H; Polat, A; Sagir, M; Samdanci, E; Sarihan, ME, 2013
)
1.83

Pharmacokinetics

The pharmacokinetic properties and hemodynamic effect of molsidomine and its pharmacologically active metabolite SIN-1 were investigated in 13 healthy volunteers following single oral doses. After a 2 mg oral administration, molsodomine elimination half-life was prolonged in elderly subjects (1) and cirrhotic patients (13)

ExcerptReferenceRelevance
" After a 2 mg oral dose, molsidomine elimination half-life was prolonged in cirrhotic patients (13."( Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.
Advenier, C; Andrieu, J; Cordonnier, P; Doll, J; Dutot, C; Grandjean, N; Pays, M; Spreux-Varoquaux, O, 1991
)
0.91
" After a 2 mg oral administration, molsidomine elimination half-life was prolonged in elderly subjects (1."( Pharmacokinetics of molsidomine and of its active metabolite, SIN-1 (or linsidomine), in the elderly.
Advenier, C; Cordonnier, P; Ducreuzet, C; Forestier, A; Pays, M; Spreux-Varoquaux, O; Ulmer, B, 1991
)
0.88
" The pharmacokinetic parameters of molsidomine were similar to already published data in healthy volunteers and patients."( Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
Chamberlain, J; Gärtner, W; Ostrowski, J; Stockhausen, H; Wildgrube, HJ, 1986
)
0.82
"The pharmacokinetic properties and hemodynamic effect of molsidomine and its pharmacologically active metabolite SIN-1 were investigated in 13 healthy volunteers following single oral doses."( Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
Brandstätter, A; Gärtner, W; Jähnchen, E; Meinertz, T; Ostrowski, J; Trenk, D, 1985
)
0.75
" The plasma half-life of molsidomine is 1 to 2 hours: it is not modified in patients with renal failure, but it is prolonged in patients with hepatic failure."( [Human pharmacokinetics of molsidomine].
Martre, H; Singlas, E, 1983
)
0.87
" After oral treatment with 2 mg molsidomine three times daily for 1 week, the pharmacokinetic parameters and the effects on heart rate and blood pressure after the final dose were not different from those after the first dose."( Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
Bergstrand, R; Chamberlain, J; Dell, D; Ostrowski, J; Peterson, LE; Stevens, LA; Vedin, A; Wilhelmsson, C, 1984
)
0.82
" The bioavailability of the parent compound after oral administration in tablet form is 44 to 59%, but further metabolism to release NO and form polar metabolites is rapid; the half-life (t-1/2) of SIN-1 is 1 to 2 hours."( Clinical pharmacokinetics of molsidomine.
Parnham, MJ; Rosenkranz, B; Winkelmann, BR, 1996
)
0.59
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3

Compound-Compound Interactions

ExcerptReferenceRelevance
"Molsidomine and its vasoactive metabolite SIN-1 elicit anti-ischemic properties by a therapeutically useful pattern of different vasoactive actions combined with a cyclic GMP-mediated inhibition of platelet adhesion and aggregation."( Anti-ischemic actions of molsidomine by venous and large coronary dilatation in combination with antiplatelet effects.
Bassenge, E; Mülsch, A, 1989
)
2.02
" Moreover, CSM dramatically enhances the production of IL-8 in combination with TNF-alpha."( IL-8 production by macrophages is synergistically enhanced when cigarette smoke is combined with TNF-alpha.
Folkerts, G; Givi, ME; Janse, WT; Mortaz, E; Nijkamp, FP; Sarir, H, 2010
)
0.36

Bioavailability

Molsidomine is well absorbed by the gastro-intestinal tract and is taken up by the liver during the first passage. The relative bioavailability of the slow release preparation in comparison to an aqueous solution of molsidumine was 0.

ExcerptReferenceRelevance
" Because of its high bioavailability when administered orally, molsidomine shows little inter-individual variations in its pharmacodynamic effects."( [Molsidomine in the treatment of coronary insufficiency].
Weber, S,
)
1.28
" Its absolute bioavailability (44 +/- 15%) and a 14C-labeled triale give evidence of quick biotransformation of molsidomine to active metabolites."( Pharmacokinetics of molsidomine in humans.
Ostrowski, J; Resag, K, 1985
)
0.8
" Trinitrin and its derivatives occupy an intermediate position because of their relatively low bioavailability after oral administration: long-term administration is not always easy and may require special modes of administration (i."( [Classification and principles of the use of vasodilators in the treatment of left ventricular insufficiency].
Cattan, S; Degeorges, M; Guérin, F; Pailleret, JJ; Weber, S, 1985
)
0.27
"Molsidomine is well absorbed by the gastro-intestinal tract and is taken up by the liver during the first passage."( [Human pharmacokinetics of molsidomine].
Martre, H; Singlas, E, 1983
)
2.01
" Additionally, plasma concentrations of molsidomine were determined to elucidate the bioavailability as well as possible correlations between plasma concentrations and antiischemic effect."( [Anti-ischemic effect of 8 mg molsidomin in retard form].
Blasini, R; Brügmann, U; Rudolph, W, 1984
)
0.54
" The bioavailability of a 2 mg oral dose of molsidomine was 44%."( Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
Bergstrand, R; Chamberlain, J; Dell, D; Ostrowski, J; Peterson, LE; Stevens, LA; Vedin, A; Wilhelmsson, C, 1984
)
0.8
"The influence of drug bioavailability on therapeutic regimens has increased the interest in in vitro dissolution testing and the quantitative interpretation of dissolution profiles."( [Reconstruction of dissolution profiles of microcapsulated formulations by the mean and variance of dissolution times (author's transl)].
Brockmeier, D, 1981
)
0.26
" The bioavailability of the parent compound after oral administration in tablet form is 44 to 59%, but further metabolism to release NO and form polar metabolites is rapid; the half-life (t-1/2) of SIN-1 is 1 to 2 hours."( Clinical pharmacokinetics of molsidomine.
Parnham, MJ; Rosenkranz, B; Winkelmann, BR, 1996
)
0.59
"Ischemia-reperfusion injury causes tissue damage that leads to a decrease in bioavailability of nitric oxide."( The effects of the nitric oxide donor SIN-1 on ischemia-reperfused cutaneous and myocutaneous flaps.
Kerrigan, CL; Khiabani, KT, 2002
)
0.31
" cell-mediated) types of action in protecting LDL against oxidation, strengthening the need for improving the knowledge of its bioavailability in humans."( Grape and grape seed extract capacities at protecting LDL against oxidation generated by Cu2+, AAPH or SIN-1 and at decreasing superoxide THP-1 cell production. A comparison to other extracts or compounds.
Carbonneau, MA; Descomps, B; Leger, CL; Shafiee, M; Urban, N, 2003
)
0.32
" We hypothesized that increasing NO bioavailability may reduce electrical remodelling induced by atrial tachycardia."( Nitric oxide delays atrial tachycardia-induced electrical remodelling in a sheep model.
Heidbüchel, H; Holemans, P; Janssens, S; Lenaerts, I; Pokreisz, P; Sipido, KR; Willems, R, 2011
)
0.37
"Nitric oxide (NO) derived from eNOS is mostly responsible for the maintenance of vascular homeostasis and its decreased bioavailability is characteristic of reactive oxygen species (ROS)-induced endothelial dysfunction (ED)."( Reversal of SIN-1-induced eNOS dysfunction by the spin trap, DMPO, in bovine aortic endothelial cells via eNOS phosphorylation.
Cardounel, AJ; Das, A; De Pascali, F; Druhan, LJ; Gopalakrishnan, B; Racoma, I; Rockenbauer, A; Varadharaj, S; Villamena, FA; Wang, TY; Zweier, JL, 2014
)
0.4
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

N-Ethoxycarbonyl-3-morpholinosydnonimine (molsidomine, Corvaton) was found to be extensively metabolized following oral dosing to rat and dog. Intravenous administration of molsidumine at increasing dosage up to 0.5 mg did not affect enzyme evaluation of infarct size. Our results suggest that the dosage of valproate in patients with coronary artery disease should be decreased.

ExcerptRelevanceReference
" Preincubation of contracted artery rings with GTP (100 microM) or guanosine (100 microM) before eliciting relaxations with nitrovasodilators significantly shifted the dose-response curves of nitrocompounds to the left and augmented the increases in cyclic GMP."( Modification of nitrovasodilator effects on vascular smooth muscle by exogenous GTP and guanosine.
Laustiola, KE; Manninen, V; Metsä-Ketelä, T; Pörsti, I; Vapaatalo, H; Vuorinen, P, 1991
)
0.28
" This is a short-term action and the dosage is limited by systemic hypotension."( [Endothelial factors and thrombocyte function].
Schrör, K, 1991
)
0.28
" Major (coronary substrate, study design) and minor (measuring devices, methods of evaluation) methodological problems make it difficult to precisely evaluate pharmacological effects such as dose-response relationship, duration of action, and selective responses, and to compare the effects of different drugs."( Response of coronary arteries to nitrates, the EDRF-donor SIN-1, and calcium antagonists.
Kober, G; Schulz, W, 1991
)
0.28
" After elevation of tone with KCl (15 mM), dose-response curves were constructed for nitroglycerin or SIN1 (3-morpholino-syndnonimin) on control and tolerant rings."( Persistence of the response to SIN1 on isolated coronary arteries rendered tolerant to nitroglycerin in vitro or in vivo.
Berkenboom, G; Degre, S; Fontaine, J, 1988
)
0.27
" Furthermore, the inhibition of 45Ca2+ uptake and of fluorescence increase observed in the presence of extracellular Ca2+ displayed remarkably parallel dose-response curves, suggesting that elevation of cyclic GMP brought about by SIN-1 inhibits the opening of "receptor-operated channels" whose precise nature remains to be determined."( Inhibition of calcium influx in thrombin-stimulated platelets by SIN-1, an activator of soluble guanylate cyclase.
Chap, H; Simon, MF, 1989
)
0.28
" As a result, the dose-response curve of SIN-1 was shifted to the left."( Interaction between SIN-1 and prostacyclin in inhibiting platelet aggregation.
Bult, H; Fret, HR; Herman, AG, 1989
)
0.28
" When the strips were treated with submaximal effective concentrations of NO, some tolerance was observed, as shown by moderate attenuation of the rises in cyclic GMP, and a rightward shift of the dose-response curve of the relaxing effects by a dose factor of 10 (DF = 10)."( Tolerance and cross-tolerance between SIN-1 and nitric oxide in bovine coronary arteries.
Holzmann, S; Kukovetz, WR, 1989
)
0.28
" However, in class III, there was a significant shift to the right of the dose-response curves to nitroglycerin and SIN1 (but not to forskolin)."( Alterations of beta-adrenoceptor mediated relaxations of atherosclerotic human coronary arteries.
Berkenboom, G; Degre, S; Fontaine, J, 1989
)
0.28
"Prolonged administration of nitroglycerin and its derivatives results in pharmacodynamic tolerance: although the dosage of these drugs is kept at the same level, their therapeutic effects decrease in amplitude."( [Comparative course of maintenance of the effects of nitrite derivatives and molsidomine after prolonged administration].
Degeorges, M; Weber, S, 1988
)
0.5
"Combinations of antianginal drugs may be used for an additive effect against angina, but also to off-set unwanted effects of one drug with another, either by direct effects or by a reduction of dosage of each drug."( Interactions of vasodilators with calcium entry- and beta-blockers in patients with coronary heart disease.
Adam, WE; Haerer, W; Henze, E; Hermann, T; Kohler, J; Kress, P; Stauch, M, 1986
)
0.27
" There was not a significant difference between the molsidomine and placebo groups regarding the enzyme evaluation of infarct size, neither for CK dosage (101."( The influence of molsidomine on infarct size: an acute post-infarction pilot study with 303 patients.
Beaufils, P; Castaigne, A; Haiat, R; Kolsky, H; Slama, R, 1988
)
0.87
" SIN 1 and SIN 1C show that the applied dosage was sufficient to reach a constant concentration over the whole period of observation in the dog."( The influence of molsidomine on myocardial ischemia and ventricular dynamics. An in-vivo study in anesthetized dogs by means of computer tomography.
Eichelkraut, W; Hahn, N; Kulle, G; Lackner, K; Stahn, L; von Uexküll-Güldenband, V,
)
0.47
"Plasma levels of N-carboxy-3-morpholinosydnonimine ethyl ester (molsidomine, Corvaton) and its pharmacologically active metabolite 3-morpholinosydnonimine (SIN-1) were measured in six healthy male and female volunteers after single intravenous and oral dosing of 4 mg molsidomine."( Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
Chamberlain, J; Gärtner, W; Ostrowski, J; Stockhausen, H; Wildgrube, HJ, 1986
)
0.78
"[14C]N-Ethoxycarbonyl-3-morpholinosydnonimine (molsidomine, Corvaton) was found to be extensively metabolized following oral dosing to rat and dog and intravenous dosing to rabbit."( The metabolism of [14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in laboratory animals.
Fromson, JM; Illing, HP; Troke, J; Watson, KV; Wilson, ID, 1986
)
0.77
"The pharmacokinetics of molsidomine were investigated in the plasma and urine of healthy male volunteers and patients with coronary heart disease after intravenous and/or oral administration of different galenic dosage forms of molsidomine."( Pharmacokinetics of molsidomine in humans.
Ostrowski, J; Resag, K, 1985
)
0.9
" At conventional dosage the most important action of nitrates is a pooling of blood in the large systemic venous capacitance vessels which leads to a decrease of central venous pressure and ventricular filling pressure."( [Effect of nitrates, nitrate-like substances, calcium antagonists and beta-adrenergic receptor blockers on peripheral circulation].
Bassenge, E; Busse, R, 1982
)
0.26
"The profile of cumulative amount released from a solid dosage form, observed in an in vitro liberation apparatus, represents the cumulative frequency of the residence times of drug molecules in the galenic formulation."( In vitro--in vivo correlation, a time scaling problem? Basic considerations on in vitro dissolution testing.
Brockmeier, D; von Hattingberg, HM, 1982
)
0.26
" Moreover, oxyhemoglobin, a scavenger of free NO, suppressed the chemotactic effect of SNAP, whereas LY-83583, a soluble guanylate cyclase inhibitor, inhibited the SNAP-mediated chemotaxis in a dose-response manner."( Exogenous nitric oxide elicits chemotaxis of neutrophils in vitro.
Beauvais, F; Dubertret, L; Michel, L, 1995
)
0.29
"The combination of hydralazine and nitrates has been shown to provide long-term benefit in congestive heart failure, despite a nitrate dosage that should induce tolerance."( Interaction between hydralazine and nitrovasodilators in vascular smooth muscle.
Berkenboom, G; Fontaine, J; Unger, P, 1993
)
0.29
" PGE1 always achieved the best response, SIN-1 performed statistically significantly poorer irrespective of the dosage used."( Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction.
Klän, R; Knispel, HH; Meier, T; Miller, K; Wegner, HE, 1994
)
0.29
" Nitroglycerin pre-exposure (10 microM for 30 min) provoked a significant shift to the right of the dose-response curve to nitroglycerin in aortae isolated from rats of 8 weeks, 12 and 18 months."( Nitrate tolerance and aging in isolated rat aorta.
Berkenboom, G; Brékine, D; Fontaine, J; Unger, P, 1993
)
0.29
" The differences between aorto-caval fistula rats and sham operated rats were probably the result of increased basal EDRF-NO release in the former, since NO synthase blockade abolished the differences in both aortic cGMP and the dose-response curve to Sin-1."( Vascular relaxation and cyclic guanosine monophosphate in a rat model of high output heart failure.
Arnal, JF; Michel, JB; Schott, C; Stoclet, JC, 1993
)
0.29
"Pharmacokinetic measurements were performed in two groups of patients with coronary heart disease (CHD) after single and multiple dosing of 2 mg linsidomine (SIN 1)."( Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency.
Degré, S; Gaertner, W; Ostrowski, J; Sennesael, J; Stolear, JC; Unger, P; Verbeelen, D; von Hattingberg, HM, 1993
)
0.29
" In general, due to a large therapeutic dose range, dosage adjustments are not required on the basis of clinical experience."( Clinical pharmacokinetics of molsidomine.
Parnham, MJ; Rosenkranz, B; Winkelmann, BR, 1996
)
0.59
" Notably, nearly identical dose-response curves were obtained when corresponding molar quantities of the most potent agents, SNP and SIN-1, were applied either via transbronchial or via intravascular routes, with respect to rapidity of onset, extent (pressure reduction to near baseline) and duration (>90 min) of vasorelaxation."( Efficiency of aerosolized nitric oxide donor drugs to achieve sustained pulmonary vasodilation.
Grimminger, F; Mayer, K; Otterbein, J; Schütte, H; Seeger, W; Spriestersbach, R; Walmrath, D, 1997
)
0.3
" In an initial dose-response study, rats received intraperitoneal (i."( Impaired learning in rats in a 14-unit T-maze by 7-nitroindazole, a neuronal nitric oxide synthase inhibitor, is attenuated by the nitric oxide donor, molsidomine.
Ingram, DK; London, ED; Meyer, RC; Patel, N; Spangler, EL, 1998
)
0.5
" The dose-response function of both those psychostimulants did not change in the course of the experiment."( The role of the nitric oxide (NO) pathway in the discriminative stimuli of amphetamine and cocaine.
Filip, M; Przegaliński, E, 1998
)
0.3
" However, the inhibition of the combined CPA and CCh response was reduced and the dose-response curve of SIN-1 shifted to the right."( Involvement of intracellular Ca2+ stores in inhibitory effects of NO donor SIN-1 and cGMP.
Allescher, HD; Franck, H; Puschmann, A; Schusdziarra, V; Storr, M, 1998
)
0.3
" Acetaminophen is a phenolic compound which produces a clear inhibitory dose-response curve with peroxynitrite in its range of clinical effectiveness."( A new screening method to detect water-soluble antioxidants: acetaminophen (Tylenol) and other phenols react as antioxidants and destroy peroxynitrite-based luminol-dependent chemiluminescence.
Qazi, N; Sacks, M; Van Dyke, K,
)
0.13
"05) in all prostanoids evaluated in a dose-response fashion."( Nitric oxide inhibits prostanoid synthesis in the rat oviduct.
Farina, M; Franchi, AM; Gimeno, M; Ogando, D; Perez Martinez, S; Ribeiro, ML, 2000
)
0.31
"01); (3) in the presence of L-arginine (a substrate of NO synthase), a left shift of the ACh dose-response curves was found in control subjects, but not in ADPKD patients; (4) in the presence of the N(G)-nitro-L-arginine methyl ester (an inhibitor of NO synthase), a right shift of the ACh dose-response curve was found in control subjects, but not in ADPKD patients; and (5) endothelium-independent relaxation rate induced with SIN-1 was similar in patients and control subjects."( Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease.
Iversen, J; Strandgaard, S; Wang, D, 2000
)
0.31
" ODQ (1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one), a potent and selective inhibitor of soluble guanylyl cyclase (sGC), did not significantly affect relaxant actions of ONOO-, but ODQ markedly attenuated SIN-1-elicited relaxation with a rightward shift in the dose-response curve and an unaltered maximal response."( Comparative vasodilation of peroxynitrite and 3-morpholinosydnonimine.
Trakranrungsie, N; Will, JA, 2001
)
0.31
" Our results suggest that the dosage of valproate in patients with coronary artery disease treated with molsidomine should be decreased."( Molsidomine enhances the protective activity of valproate against pentylenetetrazole-induced seizures in mice.
Arent, K; Kleinrok, Z; Tutka, P; Wielosz, M; Łuszczki, J, 2002
)
1.97
" In a first dose-response study, L-NAME, at 30 but not at 10 mg/kg impaired the animals' performance, whereas at 60 mg/kg, it induced side-effects."( Molsidomine attenuates N(omega)-nitro-L-argininemethylester-induced deficits in a memory task in the rat.
Cella, SG; Muller, EE; Pitsikas, N; Rigamonti, AE, 2002
)
1.76
" unstimulated conditions), the nitric oxide synthase (NOS) inhibitor L-NIO (L-N(5)-(1-iminoethyl) ornithine, 10(-5) and 10(-4) M), caused a marked vasoconstriction (20%), indicating a basal nitrergic vasodilator tone, while the dose-response curve of the NO donor SIN-1 (3-morpholinosydnonimine) showed a dose-dependent vasodilator effect."( Control of cardiovascular function in the icefish Chionodraco hamatus: involvement of serotonin and nitric oxide.
Acierno, R; Pellegrino, D; Tota, B, 2003
)
0.32
" In a first dose-response study, baclofen (0."( The GABAB receptor and recognition memory: possible modulation of its behavioral effects by the nitrergic system.
Cella, SG; Muller, EE; Pitsikas, N; Rigamonti, AE, 2003
)
0.32
" dosage regimen."( A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations.
Carreer-Bruhwyler, F; Chiap, P; Crommen, J; Dubois, C; Famaey, JP; Fenyvesi, T; Géczy, J; Hubert, P; Messin, R, 2003
)
0.56
" In the first dose-response study, post-training administration of 8-OH-DPAT (0."( The 5-HT1A receptor and recognition memory. Possible modulation of its behavioral effects by the nitrergic system.
Pitsikas, N; Sakellaridis, N; Tsitsirigou, S; Zisopoulou, S, 2005
)
0.33
" In both dogfish and eel, AD dose-response curves showed a biphasic effect: vasoconstriction (pico to nanomolar range) and vasodilation (micromolar range)."( Adenosine/nitric oxide crosstalk in the branchial circulation of Squalus acanthias and Anguilla anguilla.
Pellegrino, D; Randall, DJ; Tota, B, 2005
)
0.33
" In a first dose-response study, post-training administration of memantine (10 and 20, but not 3 mg/kg) antagonized recognition memory deficits in the rat, suggesting that memantine modulates storage and/or retrieval of information."( Memantine and recognition memory: possible facilitation of its behavioral effects by the nitric oxide (NO) donor molsidomine.
Pitsikas, N; Sakellaridis, N, 2007
)
0.55
"Each of the single topical drugs produced significant dose-dependent antiallodynic effects compared with vehicle in CPIP rats (N = 30), and the antiallodynic dose-response curves of either PA or PDE inhibitors were shifted 5- to 10-fold to the left when combined with nonanalgesic doses of α2A receptor agonists or NO donors (N = 28)."( Topical combinations to treat microvascular dysfunction of chronic postischemia pain.
Abaji, R; Coderre, TJ; Laferrière, A; Ragavendran, JV; Tsai, CY, 2014
)
0.4
" Myocytes superfused with 3-morpholinosydnonimine N-ethylcarbamide (SIN-1), an ONOO- donor, decreased the amplitude of Ca2+ transients and contraction in a dose-response (1-200 μM) manner."( Peroxynitrite-Induced Intracellular Ca2+ Depression in Cardiac Myocytes: Role of Sarco/Endoplasmic Reticulum Ca2+ Pump.
Escalante, B; Flores-Tamez, V; Rios, A, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
nitric oxide donorAn agent, with unique chemical structure and biochemical requirements, which generates nitric oxide.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
cardioprotective agentAny protective agent that is able to prevent damage to the heart.
vasodilator agentA drug used to cause dilation of the blood vessels.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
nitric oxide donorAn agent, with unique chemical structure and biochemical requirements, which generates nitric oxide.
apoptosis inhibitorAny substance that inhibits the process of apoptosis (programmed cell death) in multi-celled organisms.
cardioprotective agentAny protective agent that is able to prevent damage to the heart.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
morpholinesAny compound containing morpholine as part of its structure.
morpholinesAny compound containing morpholine as part of its structure.
oxadiazole
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
morpholinesAny compound containing morpholine as part of its structure.
morpholinesAny compound containing morpholine as part of its structure.
oxadiazole
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
zwitterionA neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (46)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency8.91250.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency28.59910.044717.8581100.0000AID485294; AID485341
endonuclease IVEscherichia coliPotency10.00000.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency26.67950.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.66030.006038.004119,952.5996AID1159521
Smad3Homo sapiens (human)Potency2.81840.00527.809829.0929AID588855
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.31620.00137.762544.6684AID914; AID915
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency25.11510.001022.650876.6163AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency26.60320.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency5.30800.001530.607315,848.9004AID1224821
estrogen nuclear receptor alphaHomo sapiens (human)Potency12.74480.000229.305416,493.5996AID743080
arylsulfatase AHomo sapiens (human)Potency21.33131.069113.955137.9330AID720538
IDH1Homo sapiens (human)Potency14.58100.005210.865235.4813AID686970
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00080.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency100.00000.006026.168889.1251AID540317
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.01260.010039.53711,122.0200AID1479
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency7.94330.15855.287912.5893AID540303
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.25890.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency7.94330.00106.000935.4813AID944
lamin isoform A-delta10Homo sapiens (human)Potency6.30960.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency19.95260.015812.3113615.5000AID1461
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.25891.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Estrogen receptor 1Homo sapiens (human)IC50 (µMol)24.67392.161613.689226.3472AID713
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (41)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (17)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (91)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1503958Antiglaucoma activity in hypertonic saline-induced New Zealand albino rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 1% dose administered topically immediately after hypertonic saline injection measured at 120 mins post do2017ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1503953Vasodilatory activity in denuded Wistar rat thoracic aorta assessed as relaxation of L-phenylephrine-induced contractions of aortic strips2017ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1503959Antiglaucoma activity in hypertonic saline-induced New Zealand albino rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 1% dose administered topically immediately after hypertonic saline injection measured at 240 mins post do2017ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10
AID1503954Vasodilatory activity in denuded Wistar rat thoracic aorta assessed as relaxation of L-phenylephrine-induced contractions of aortic strips in presence of 1 uM of soluble guanylate cyclase inhibitor ODQ2017ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1278452Half life of compound at pH 7.42016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Design and synthesis of novel hybrid sydnonimine and prodrug useful for glaucomatous optic neuropathy.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1503957Antiglaucoma activity in hypertonic saline-induced New Zealand albino rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 1% dose administered topically immediately after hypertonic saline injection measured at 60 mins post dos2017ACS medicinal chemistry letters, Oct-12, Volume: 8, Issue:10
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1434528Antiglaucoma activity in hypertonic saline-induced New Zealand white rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 30 uL administered topically immediately after hypertonic saline injection measured at 60 mins post dose2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
New furoxan derivatives for the treatment of ocular hypertension.
AID1434527Antiglaucoma activity in hypertonic saline-induced New Zealand white rabbit transient ocular hypertensive model assessed as IOP lowering efficacy at 30 uL administered topically immediately after hypertonic saline injection measured at 120 mins post dose2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
New furoxan derivatives for the treatment of ocular hypertension.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,971)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990289 (14.66)18.7374
1990's817 (41.45)18.2507
2000's670 (33.99)29.6817
2010's177 (8.98)24.3611
2020's18 (0.91)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.96

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.96 (24.57)
Research Supply Index7.68 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index114.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.96)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials148 (7.32%)5.53%
Trials0 (0.00%)5.53%
Reviews51 (2.52%)6.00%
Reviews1 (3.45%)6.00%
Case Studies14 (0.69%)4.05%
Case Studies0 (0.00%)4.05%
Observational3 (0.15%)0.25%
Observational0 (0.00%)0.25%
Other1,806 (89.32%)84.16%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind Parallel Placebo-controlled Study to Evaluate the Effect of Molsidomine on the Endothelial Dysfunction in Patients With Stable Angina Pectoris Undergoing a Percutaneous Coronary Intervention [NCT01363661]Phase 4165 participants (Actual)Interventional2011-06-30Completed
Swiss Interventional Study on Silent Ischemia (SWISSI 1) [NCT00382421]0 participants Interventional1992-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01363661 (6) [back to overview]Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12).
NCT01363661 (6) [back to overview]Change Versus Baseline in the Score of the EndoPAT in the Two Groups After Six Months of Treatment (Month 6).
NCT01363661 (6) [back to overview]Frequency of Serious Cardiovascular Events (SCEs) in the Two Groups After Twelve Months of Treatment (Month 12).
NCT01363661 (6) [back to overview]Change Versus Baseline in Some Specific Endothelial Biomarkers After Twelve Months of Treatment (Month 12).
NCT01363661 (6) [back to overview]Change Versus Baseline in the Augmentation Index in the Two Groups After Six and Twelve Months of Treatment (Months 6 and 12).
NCT01363661 (6) [back to overview]Frequency of AEs and SAEs in the Two Groups After Twelve Months of Treatment (Month 12).

Change Versus Baseline in the Score of the EndoPAT in the Two Groups After One Year of Treatment (Month 12).

The results are expressed mean relative change (%) between month 12 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 12. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -275% and the maximum observed was +4200%. (NCT01363661)
Timeframe: 12 months

InterventionRelative change versus baseline (%) (Mean)
Molsidomine330.60
Placebo164.08

[back to top]

Change Versus Baseline in the Score of the EndoPAT in the Two Groups After Six Months of Treatment (Month 6).

The results are expressed mean relative change (%) between month 6 and baseline. A positive result means improvement in the score of the EndoPAT between baseline and month 6. It could be considered as a surrogate of a decrease of the endothelial dysfunction. A negative percentage means the inverse. The are no fixed limits to the scale. The minimum observed was -200% and the maximum observed was +6100%. (NCT01363661)
Timeframe: Month 6

InterventionRelative change versus baseline (%) (Mean)
Molsidomine361.98
Placebo326.26

[back to top]

Frequency of Serious Cardiovascular Events (SCEs) in the Two Groups After Twelve Months of Treatment (Month 12).

Sum of the events collected during 12 months. (NCT01363661)
Timeframe: Month 12

InterventionNumber of events (Number)
Molsidomine3
Placebo1

[back to top]

Change Versus Baseline in Some Specific Endothelial Biomarkers After Twelve Months of Treatment (Month 12).

(NCT01363661)
Timeframe: Month 12

,
InterventionRelative change versus baseline (%) (Mean)
Endothelial microparticlesPlatelet microparticlesLeukocyte microparticlessICAM-1IL-8hs-CRPMOX-LDLMPO antigenMPO activityMPO activity/antigen ratio
Molsidomine-400.5-39-613-5011-1-43-42
Placebo-40-23-376-25-3541-3287

[back to top]

Change Versus Baseline in the Augmentation Index in the Two Groups After Six and Twelve Months of Treatment (Months 6 and 12).

The results are expressed mean relative change (%) between month 6 or month 12, and baseline. A positive result means improvement in the augmentation index between baseline and month 6 or month 12. It could be considered as a surrogate of a decrease of the arterial stiffness. A negative percentage means the inverse. The are no fixed limits to the scale. At month 6,the minimum observed was -139% and the maximum observed was +1600%.At month 12, the minimum observed was -524% and the maximum observed was +1600%. (NCT01363661)
Timeframe: Month 6 and Month 12

,
InterventionRelative change versus baseline (%) (Mean)
Month 6Month 12
Molsidomine218.0798.57
Placebo96.3595.13

[back to top]

Frequency of AEs and SAEs in the Two Groups After Twelve Months of Treatment (Month 12).

Sum of the events collected during 12 months. (NCT01363661)
Timeframe: Month 12

,
InterventionNumber of events (Number)
Non-serious AESAE
Molsidomine577
Placebo7912

[back to top]